Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,212 JPY | -0.67% | -0.74% | -11.41% |
Feb. 28 | Aeon Co. Plans to Merge Japan Drugstore Unit Welcia With Rival Tsuruha -- 2nd Update | DJ |
Feb. 28 | Aeon Co. Plans to Merge Japan Drugstore Unit Welcia With Rival Tsuruha -- Update | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.41% | 5.86B | C+ | ||
-32.21% | 15.27B | B- | ||
-31.97% | 10.84B | B | ||
-30.42% | 6.06B | B | ||
+8.14% | 6.04B | C | ||
-0.88% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-12.31% | 3.61B | B | ||
-14.86% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3088 Stock
- Ratings MatsukiyoCocokara & Co.